March 2016

Contents

Editorial

• March/April 2016: Volume 17 Number 3/4

Conference reports

• 23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston

• Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study

• New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP

• Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART

• 48-week results for NNRTI doravirine compared to efavirenz

• Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions

• Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots

• First data on TAF as PrEP to prevent HIV infection

• Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections

• Role for maraviroc as HIV PrEP likely to need dual combinations

• Dapivirine PrEP vaginal ring shows only limited PrEP protection against HIV in African women

• Early data from dolutegravir use during pregnancy

• Dolutegravir: 48 week results in children age 6 to 12 years old

• New antiretrovirals could mean savings up to US $3 billion by 2025

• Countries with lower HIV prevalence have lower ART coverage

• Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals

• Cure research news from CROI 2016

Antiretrovirals

• EU adopts positive opinion on dual formulation of F/TAF

• New TAF-containing fixed dose combination approved in the US

Treatment access

• Community oppose dolutegravir and cabotegravir patents in India

• MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years

• Global Fund provides Uganda with a year of drugs to meet shortages

• Transgender people left behind in the fight against HIV: Only 17 out of 130 countries have transgender representatives

• Mbeki shows no remorse for role in AIDS deaths

Side effects

• Alcohol risks are higher in HIV positive people and linked to increased mortality

HIV prevention and transmission

• Canada approves TDF/FTC as PrEP

• NHS England pulls proposed timeline for PrEP: perpetuates HIV health crisis in gay men and trans people

• UK community campaign calls for NHS England to be accountable for PrEP timeline

Other news

• HIV positive transplant donors approved in the US

PDFs

• March/April 2016: Volume 17 Number 3/4